{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:18:56Z","timestamp":1780352336726,"version":"3.54.1"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In patients with chronic heart failure (CHF), the use of angiotensin-converting enzyme inhibitors, including ramipril, is recommended to reduce the risk of heart failure worsening, hospitalisation, and death. Our aim was to investigate the influence of body composition on the pharmacokinetics of ramipril and its active metabolite ramiprilat and to evaluate the changes in pharmacokinetics after prolonged therapy. Twenty-three patients with CHF who were on regular therapy with ramipril participated at the first study visit ( median age 77 years, 65 % male, and 70 % New York Heart Association Class II); 19 patients attended the second study visit and the median time between the two visits was 8 months. Pharmacokinetics were assessed using a nonlinear mixed-effects parent-metabolite model comprising two compartments for ramipril and one compartment for ramiprilat. The influence of body size and composition was best described by an allometric relationship with fat-free mass. In addition, ramipril clearance was related to patient age and daily ramipril dose, while clearance of ramiprilat was influenced by glome rular filtration rate and daily ramipril dose. There were no clinically relevant changes in the pharmacokinetics of ramipril and ramiprilat between the study visits. Due to the relatively stable pharmacokinetics of ramipril, regular outpatient visits at 6-month intervals seem appropriate to evaluate ramipril therapy.<\/jats:p>","DOI":"10.2478\/acph-2024-0018","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T12:15:01Z","timestamp":1717071301000},"page":"315-328","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics of ramipril in patients with chronic heart failure: A real-world longitudinal study"],"prefix":"10.2478","volume":"74","author":[{"given":"Katja \u010cvan","family":"Trobec","sequence":"first","affiliation":[{"name":"University of Ljubljana Faculty of Pharmacy Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-1499","authenticated-orcid":false,"given":"Iztok","family":"Grabnar","sequence":"additional","affiliation":[{"name":"University of Ljubljana Faculty of Pharmacy Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurij","family":"Trontelj","sequence":"additional","affiliation":[{"name":"University of Ljubljana Faculty of Pharmacy Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-4098","authenticated-orcid":false,"given":"Mitja","family":"Lain\u0161\u010dak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Ljubljana Ljubljana , Slovenia"},{"name":"Division of Cardiology General Hospital Murska Sobota , Murska Sobota Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-6739","authenticated-orcid":false,"given":"Mojca Kerec","family":"Kos","sequence":"additional","affiliation":[{"name":"University of Ljubljana Faculty of Pharmacy Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"#cr-split#-2026051108213905546_j_acph-2024-0018_ref_001.1","doi-asserted-by":"crossref","unstructured":"S. Stewart, I. Ekman, T. Ekman, A. Oden and A. Rosengren, Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004), Circ. Cardiovasc. Qual. Outcomes 3(6) (2010) 573-580","DOI":"10.1161\/CIRCOUTCOMES.110.957571"},{"key":"#cr-split#-2026051108213905546_j_acph-2024-0018_ref_001.2","unstructured":"S. Stewart, I. Ekman, T. Ekman, A. Oden and A. Rosengren, Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004), Circ. Cardiovasc. Qual. Outcomes 3"},{"key":"#cr-split#-2026051108213905546_j_acph-2024-0018_ref_001.3","doi-asserted-by":"crossref","unstructured":"(6) (2010) 573-580; https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.957571","DOI":"10.1161\/CIRCOUTCOMES.110.957571"},{"key":"#cr-split#-2026051108213905546_j_acph-2024-0018_ref_002.1","doi-asserted-by":"crossref","unstructured":"T. A. McDonagh, M. Metra, M. Adamo, R. S. Gardner, A. Baumbach, M. B\u00f6hm, H. Burri, J. Butler, J. \u010celutkien\u0117, O. Chioncel, J. G. F. Cleland, A. J. S. Coats, M. G. Crespo-Leiro, D. Farmakis, M. Gi-lard, S. Heymans, A. W. Hoes, T. Jaarsma, E. A. Jankowska and A. K. Skibelund, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J. 42(36) (2021) 3599-3726","DOI":"10.1093\/eurheartj\/ehab670"},{"key":"#cr-split#-2026051108213905546_j_acph-2024-0018_ref_002.2","unstructured":"T. A. McDonagh, M. Metra, M. Adamo, R. S. Gardner, A. Baumbach, M. B\u00f6hm, H. Burri, J. Butler, J. \u010celutkien\u0117, O. Chioncel, J. G. F. Cleland, A. J. S. Coats, M. G. Crespo-Leiro, D. Farmakis, M. Gi-lard, S. Heymans, A. W. Hoes, T. Jaarsma, E. A. Jankowska and A. K. Skibelund, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J. 42"},{"key":"#cr-split#-2026051108213905546_j_acph-2024-0018_ref_002.3","doi-asserted-by":"crossref","unstructured":"(36) (2021) 3599-3726; https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2026051108213905546_j_acph-2024-0018_ref_003","doi-asserted-by":"crossref","unstructured":"E. Lonn, Dose response of ACE inhibitors: implications of the SECURE trial, Trials 2(4) (2001) 155\u2013159; https:\/\/doi.org\/10.1186\/cvm-2-4-155","DOI":"10.1186\/cvm-2-4-155"},{"key":"2026051108213905546_j_acph-2024-0018_ref_004","doi-asserted-by":"crossref","unstructured":"D. S. Roffman, High-versus low-dose ACE inhibitor therapy in chronic heart failure. Ann. Pharmacother. 38(5) (2004) 831\u2013838; https:\/\/doi.org\/10.1345\/aph.1C402","DOI":"10.1345\/aph.1C402"},{"key":"2026051108213905546_j_acph-2024-0018_ref_005","doi-asserted-by":"crossref","unstructured":"E. R. Debusmann, J. O. Pujadas, W. Lahn, R. Irmisch, F. Jane, T. S. Kuan, J. Mora, U. Walter, H. G. Eckert, P. Hajdu and H. Metzger, Influence of renal function on the pharmacokinetics of ramipril (HOE 498), Am. J. Cardiol. 59(10) (1987) 70D\u201378D; https:\/\/doi.org\/10.1016\/0002-9149(87)90057-9","DOI":"10.1016\/0002-9149(87)90057-9"},{"key":"2026051108213905546_j_acph-2024-0018_ref_006","doi-asserted-by":"crossref","unstructured":"J. M. van Griensven, R. C. Schoemaker, A. F. Cohen, H. G. Luus, M. Seibert-Grafe and H. J. Rothig, Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril, Eur. J. Clin. Pharmacol. 47(6) (1995) 513\u2013518. https:\/\/doi.org\/10.1007\/BF00193704","DOI":"10.1007\/BF00193704"},{"key":"2026051108213905546_j_acph-2024-0018_ref_007","doi-asserted-by":"crossref","unstructured":"D. G. Levitt and R. C. Schoemaker, Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat, BMC Clin. Pharmacol. 6(1) (2006); https:\/\/doi.org\/10.1186\/1472-6904-6-1","DOI":"10.1186\/1472-6904-6-1"},{"key":"2026051108213905546_j_acph-2024-0018_ref_008","doi-asserted-by":"crossref","unstructured":"B. Beermann, O. Nyquist, C. Hoglund, K. A. Jacobsson, U. Naslund and M. Jensen-Urstad, Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study, Eur. J. Clin. Pharmacol 45(3) (1993) 241\u2013246; https:\/\/doi.org\/10.1007\/BF00315390","DOI":"10.1007\/BF00315390"},{"key":"2026051108213905546_j_acph-2024-0018_ref_009","doi-asserted-by":"crossref","unstructured":"H. Schunkert, J. Kindler, M. Gassmann, W. Lahn, R. Irmisch, E. Ritz, E. R. Debusmann, J. O. Puja das, K. M. Koch and H. G. Sieberth, Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency, Eur. J. Clin. Pharmacol. 37(3) (1989) 249\u2013256; https:\/\/doi.org\/10.1007\/BF00679779","DOI":"10.1007\/BF00679779"},{"key":"2026051108213905546_j_acph-2024-0018_ref_010","doi-asserted-by":"crossref","unstructured":"M. Verho, C. Luck, W. J. Stelter, B. Rangoonwala and N. Bender, Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man, Curr. Med. Res. Opin. 13(5) (1995) 264\u2013273; https:\/\/doi.org\/10.1185\/03007999509111551","DOI":"10.1185\/03007999509111551"},{"key":"2026051108213905546_j_acph-2024-0018_ref_011","doi-asserted-by":"crossref","unstructured":"U. Gerckens, E. Grube, T. Mengden, H. Sigel, W. L. Wagner, T. Lahn, R. Irmisch and H. Metzger, Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV), J. Cardiovasc. Pharmacol. 13 Suppl 3 (1989) S49\u201351; https:\/\/doi.org\/10.1097\/00005344-198900133-00012","DOI":"10.1097\/00005344-198900133-00012"},{"key":"2026051108213905546_j_acph-2024-0018_ref_012","doi-asserted-by":"crossref","unstructured":"B. Heintz, M. Verho, D. Brockmeier, G. Luckel, S. Maigatter, H. G. Sieberth, B. Rangoonwala and N. Bender, Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure, J. Cardiovasc. Pharmacol. 22 Suppl 9 (1993) S36\u201342.","DOI":"10.1097\/00005344-199312002-00008"},{"key":"2026051108213905546_j_acph-2024-0018_ref_013","doi-asserted-by":"crossref","unstructured":"G. Loncar, J. Springer, M. Anker, W. Doehner and M. Lainscak, Cardiac cachexia: hic et nunc, J. Cachexia Sarcopenia Muscle 7(3) (2016) 246\u201360; https:\/\/doi.org\/10.1002\/jcsm.12118","DOI":"10.1002\/jcsm.12118"},{"key":"2026051108213905546_j_acph-2024-0018_ref_014","doi-asserted-by":"crossref","unstructured":"S. Khan and A. Shahzadi, Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review, Drug Metab. Rev. 51(1) (2019) 1\u201311. https:\/\/doi.org\/10.1080\/03602532.2018.1508226","DOI":"10.1080\/03602532.2018.1508226"},{"key":"2026051108213905546_j_acph-2024-0018_ref_015","doi-asserted-by":"crossref","unstructured":"K. Trobec, M. Kerec Kos, S. von Haehling, J. Springer, S. D. Anker and M. Lainscak, Pharmacokinetics of drugs in cachectic patients: a systematic review, PLoS One 8(11) (2013) e79603 (10 pages); https:\/\/doi.org\/10.1371\/journal.pone.0079603","DOI":"10.1371\/journal.pone.0079603"},{"key":"2026051108213905546_j_acph-2024-0018_ref_016","doi-asserted-by":"crossref","unstructured":"S. Janmahasatian, S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne and B. Green, Quantification of lean bodyweight, Clin. Pharmacokinet. 44(10) (2005) 1051\u20131065; https:\/\/doi.org\/10.2165\/00003088-200544100-00004","DOI":"10.2165\/00003088-200544100-00004"},{"key":"2026051108213905546_j_acph-2024-0018_ref_017","doi-asserted-by":"crossref","unstructured":"L. I. Cortinez, B. J. Anderson, N. H. Holford, V. Puga, N. de la Fuente, H. Auad, S. Solari, F. A. Allende and M. Ibacache, Dexmedetomidine pharmacokinetics in the obese. Eur. J. Clin. Pharmacol. 71(12) (2015) 1501\u20131508; https:\/\/doi.org\/10.1007\/s00228-015-1948-2","DOI":"10.1007\/s00228-015-1948-2"},{"key":"2026051108213905546_j_acph-2024-0018_ref_018","doi-asserted-by":"crossref","unstructured":"I. Janssen, R. N. Baumgartner, R. Ross, I. H. Rosenberg and R. Roubenoff, Skeletal muscle cut-points associated with elevated physical disability risk in older men and women, Am. J. Epidemiol. 159(4) (2004) 413\u2013421; https:\/\/doi.org\/10.1093\/aje\/kwh058","DOI":"10.1093\/aje\/kwh058"},{"key":"2026051108213905546_j_acph-2024-0018_ref_019","doi-asserted-by":"crossref","unstructured":"I. Janssen, S. B. Heymsfield, R. N. Baumgartner and R. Ross, Estimation of skeletal muscle mass by bioelectrical impedance analysis, J. Appl. Physiol. 89(2) (2000) 465\u2013471; https:\/\/doi.org\/10.1152\/jappl.2000.89.2.465","DOI":"10.1152\/jappl.2000.89.2.465"},{"key":"2026051108213905546_j_acph-2024-0018_ref_020","doi-asserted-by":"crossref","unstructured":"O. Gonz\u00e1lez, M. E. Blanco, G. Iriarte, L. Bartolom\u00e9, M. I. Maguregui and R. M. Alonso, Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect, J. Chromatogr. A 1353 (2014) 10\u201327; https:\/\/doi.org\/10.1016\/j.chroma.2014.03.077","DOI":"10.1016\/j.chroma.2014.03.077"},{"key":"2026051108213905546_j_acph-2024-0018_ref_021","doi-asserted-by":"crossref","unstructured":"C. Ghosh, Relative matrix effects: A step forward using standard line slopes and ANOVA analysis, Arab. J. Chem. 12(7) (2019) 1378\u20131386; https:\/\/doi.org\/10.1016\/j.arabjc.2014.11.019","DOI":"10.1016\/j.arabjc.2014.11.019"},{"key":"2026051108213905546_j_acph-2024-0018_ref_022","doi-asserted-by":"crossref","unstructured":"A. M. Alvarez and D. Mukherjee, Liver abnormalities in cardiac diseases and heart failure, Int. J. Angiol. 20(3) (2011)135\u2013142; https:\/\/doi.org\/10.1055\/s-0031-1284434","DOI":"10.1055\/s-0031-1284434"},{"key":"2026051108213905546_j_acph-2024-0018_ref_023","doi-asserted-by":"crossref","unstructured":"M. D. Samsky, C. B. Patel, T. A. DeWald, A. D. Smith, G. M. Felker, J. G. Rogers and A. F. Hernandez, Cardiohepatic interactions in heart failure: an overview and clinical implications, J. Am. Coll. Cardiol. 61(24) (2013) 2397\u20132405; https:\/\/doi.org\/10.1016\/j.jacc.2013.03.042","DOI":"10.1016\/j.jacc.2013.03.042"},{"key":"2026051108213905546_j_acph-2024-0018_ref_024","doi-asserted-by":"crossref","unstructured":"T. Narumi, T. Watanabe, S. Kadowaki, T. Takahashi, M. Yokoyama, D. Kinoshita, Y. Honda, A. Funayama, S. Nishiyama, H. Takahashi, T. Arimoto, T. Shishido, T. Miyamoto and I. Kubota, Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure, Eur. J. Intern. Med. 26(2) (2015) 118\u2013122; https:\/\/doi.org\/10.1016\/j.ejim.2015.01.008","DOI":"10.1016\/j.ejim.2015.01.008"},{"key":"2026051108213905546_j_acph-2024-0018_ref_025","doi-asserted-by":"crossref","unstructured":"N. H. Uszko-Lencer, F. Bothmer, P. E. van Pol and A. M. Schols, Measuring body composition in chronic heart failure: a comparison of methods, Eur. J. Heart Fail 8(2) (2006) 208\u2013214; https:\/\/doi.org\/10.1016\/j.ejheart.2005.07.007","DOI":"10.1016\/j.ejheart.2005.07.007"},{"key":"2026051108213905546_j_acph-2024-0018_ref_026","doi-asserted-by":"crossref","unstructured":"P. L. Toutain and H. P. Lefebvre, Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors, J. Vet. Pharmacol. Ther. 27(6) (2004) 515\u2013525; https:\/\/doi.org\/10.1111\/j.1365-2885.2004.00601.x","DOI":"10.1111\/j.1365-2885.2004.00601.x"},{"key":"2026051108213905546_j_acph-2024-0018_ref_027","doi-asserted-by":"crossref","unstructured":"R. Thomsen, H. B. Rasmussen, K. Linnet and INDICES Consortium, In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors, Drug Metab. Dispos. 42(1) (2014) 126\u2013133; https:\/\/doi.org\/10.1124\/dmd.113.053512","DOI":"10.1124\/dmd.113.053512"},{"key":"2026051108213905546_j_acph-2024-0018_ref_028","doi-asserted-by":"crossref","unstructured":"W. J. Gilchrist, K. Beard, P. Manhem, E. M. Thomas, J. I. Robertson and S. G. Ball, Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients, Am. J. Cardiol. 59(10) (1987) 28D\u201332D; https:\/\/doi.org\/10.1016\/0002-9149(87)90049-X","DOI":"10.1016\/0002-9149(87)90049-X"},{"key":"2026051108213905546_j_acph-2024-0018_ref_029","doi-asserted-by":"crossref","unstructured":"R. Ogawa, J. M. Stachnik and H. Echizen, Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally), Clin. Pharmacokinet. 53(12) (2014) 1083\u20131114; https:\/\/doi.org\/10.1007\/s40262-014-0189-3","DOI":"10.1007\/s40262-014-0189-3"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2024-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:55:15Z","timestamp":1778489715000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2024-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.2478\/acph-2024-0018"],"URL":"https:\/\/doi.org\/10.2478\/acph-2024-0018","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}